Posted by Michael Wonder on 28 May 2022
U.S. FDA declines to approve Eton Pharma's anti-seizure drug
27 May 2022 - Eton Pharmaceuticals said on Friday the U.S. FDA declined to approve its anti-seizure drug lamotrigine.
Eton was notified that its privately held partner Azurity Pharmaceuticals received a complete response letter from the health regulator for lamotrigine, it said in a regulatory filing.
